Abstract
Primary signet ring cell carcinomas of the bladder (PSRCCB) are extremely rare tumors. These tumors generally present as high-grade, high-stage tumors and have a uniformly poor prognosis. PSRCCB need to be differentiated from metastases from other primary sites. Clinical, imaging, and immune-histochemical findings may help in identifying the primary source of signet cell cancer. We retrospectively reviewed our series of patient identified to have primary signet cell carcinoma of the bladder. We retrospectively reviewed all case records of patients with carcinoma bladder. Only patients with a histopathological report of signet ring cell carcinoma of the bladder were included in this study. During the period Sept 1991 to Aug 2016, a total five patients (0.18%) were diagnosed to have had PSRCCB. Hematuria was the main symptom in four of the five patients. Cystoscopy/TURBT was done in all patients, and histological examination confirmed signet cell carcinoma. All the patients were counseled and underwent radical cystectomy. The mean overall survival was 28.2 ± 3.7 months. We report a small series of primary signet cell carcinoma presenting over a 25-year period with an overall incidence of 0.18%. Post radical cystectomy local recurrence/distant metastases are common and response to chemotherapy was poor. The overall outcome for signet-ring cell cancers in general is very poor.
Similar content being viewed by others
References
Wood DP (2016) Tumors of the bladder. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA (eds) Campbell Walsh urology, 11th edn. Elsevier-Saunders, Philadelphia, p 2184
Guntaka AK, Nerli RB, Malur PR, Hiremath MB (2014) Primary signet ring cell carcinoma of the urinary bladder—a case report. Int J Rec Sci Res 5:861–862
Thomas DG, Ward AM, Williams JL (1971) A study of 52 cases of adenocarcinoma of the bladder. Br J Urol 43:4–15
Michels J, Barbour S, Cavers D, Chi KN (2010) Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature. Can Urol Assoc J 4:E55–E57
Ozeki Z, Kobayashi S, Machida T et al (2003) Transitional cell carcinoma of the urinary bladder accompanied by signet-ring cell carcinoma: a case report [in Japanese]. Hinyokika Kiyo 49:411–413
Saphir O (1955) Signet-ring cell carcinoma of the urinary bladder. Am J Pathol 31:223–231
Parkin DM (2008) The global burden of urinary bladder cancer. Scand J Urol Nephrol 42:12–20
Romics I, Sze’kely E, Szendroi A (2008) Signet-ring cell carcinoma arising from the urinary bladder. Canadian Journal of Urology 15:4266–4268
Akamatsu S, Takahashi A, Ito M, Ogura K (2010) Primary signet-ring cell carcinoma of the urinary bladder. Urology 75:615–618
Fiter L, Gimeno F, Martin L, Gomez TL (1993) Signet-ring cell adenocarcinoma of bladder. Urology 41:30–33
Hamakawa T, Kojima Y, Naiki T, Kubota Y, Yasui T, Tozawa K, Hayashi Y, Kohri K (2013) Long-term survival of a patient with invasive signet-ring cell carcinoma of the urinary bladder managed by combined S-1 and cisplatin adjuvant chemotherapy. Case reports in urology:915874
Boukettaya W, Feki J, Charfi S, Toumi N, Khanfir A, Boudawara T, Daoud J, Frikha M (2014) Primary signet ring cell adenocarcinoma of the urinary bladder: a report of 2 cases. Urology Case Reports 2:85–87
Hirano Y, Suzuki K, Fujita K, Furuse H, Fukuta K, Kitagawa M et al (2002) Primary signet ring cell carcinoma of the urinary bladder successfully treated with intra-arterial chemotherapy alone. Urology 59:601
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nerli Rajendra, B., Pingale, N.D., Ghagane, S.C. et al. A Series of Primary Signet Ring Cell Carcinoma of the Urinary Bladder. Indian J Surg Oncol 8, 443–446 (2017). https://doi.org/10.1007/s13193-017-0664-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13193-017-0664-z